Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its ...

With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. | With the fate ...

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability ...

What if China decided to sever American access to the drug ingredients your sick kid depends on? But America’s losing position in the biotechnology race with China has broader implications than just ...

WuXi has disputed an early WBJ report saying construction at the Worcester site has stopped, although the company declined to ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins ...

Aadi Bioscience, Inc. ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the ...

EffiXtm is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

With streamlined processes tailored to accommodate a diverse range of project requirements from research through commercial manufacturing, the EffiX™ platform accelerates the advancement of innovative ...